Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ZBIO · against 588 other Healthcare companies listed in US-listed
Ranked #313 of 589 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including ZBIO · Click a bar to see the companies
Mainly because of its earnings yield, EBITDA yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | ZBIO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -33.8% | -4.3% | 12% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -18.2% | -0.8% | 20% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -15.7% | -2.2% | 21% | 20% | |
| Book yieldHigher is better · 587 reported | 13.7% | 24.9% | 31% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 247M USD | 98 | 80 | |
| 2 | 622M USD | 96 | 97 | |
| 2 | 441M USD | 96 | 81 | |
| 2 | 336M USD | 96 | 57 | |
| 2 | 817M USD | 96 | 69 | |
| 313 | 713M USD | 8 | 32 | |
| 313 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 3.8B USD |
| 8 |
| 28 |
| 313 | 2.6B USD | 8 | 27 |
| 313 | 492M USD | 8 | 6 |
| 313 | 1.9B USD | 8 | 23 |
| 313 | 2.6B USD | 8 | 31 |
| 313 | 385M USD | 8 |
| 313 | 2.2B USD | 8 | 20 |
| 571 | 337M USD | 0 | 33 |